In order to modulate the CXCL12/CXCR4 system in ACC, we evaluated the effects on the axis exerted by the PPARγ ligand RGZ, an anti-diabetic drug we previously demonstrated able to inhibit ACC growth in vitro and in vivo by interfering with the PI3K and ERK activity [11,12,17]. This evidence concerns the gene PPARG and adrenal cortex carcinoma.